Tumor Associated Immune Dysfunction: Immune Cells Involved and Suggested Therapies

References (97)

1. 1 Dendritic cells and the control of immunity [DOI]
2. 2 Exploring the full spectrum of macrophage activation [DOI]
3. 3 Control of Regulatory T Cell Development by the Transcription Factor Foxp3 [DOI]
4. 4 STATs in cancer inflammation and immunity: a leading role for STAT3 [DOI]
5. 5 Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm [DOI]
6. 6 Macrophage activation and polarization [DOI]
7. 7 IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity [DOI]
8. 8 The role of myeloid cells in the promotion of tumour angiogenesis [DOI]
9. 9 Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer [DOI]
10. 10 The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation [DOI]
11. 11 Macrophage polarization in tumour progression [DOI]
12. 12 Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer [DOI]
13. 13 PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells [DOI]
14. 14 CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner [DOI]
15. 15 Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function [DOI]
16. 16 NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway [DOI]
17. 17 NK cells and cancer immunosurveillance [DOI]
18. 18 Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling [DOI]
19. 19 Leukocyte composition of human breast cancer [DOI]
20. 20 Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer [DOI]
21. 21 Macrophage Responses to Hypoxia [DOI]
22. 22 Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells [DOI]
23. 23 MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy [DOI]
24. 24 STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers [DOI]
25. 25 Natural killer cells: role in local tumor growth and metastasis [DOI]
26. 26 Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? [DOI]
27. 27 Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors [DOI]
28. 28 Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions [DOI]
29. 29 Basic principles of tumor-associated regulatory T cell biology [DOI]
30. 30 Tolerogenic dendritic cells and regulatory T cells: A two-way relationship [DOI]
31. 31 Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemias [DOI]
32. 32 A Phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma [DOI]
33. 33 FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast [DOI]
34. 34 TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis [DOI]
35. 35 Dendritic Cell Interactions with NK Cells from Different Tissues [DOI]
36. 36 Neem Leaf Glycoprotein Activates CD8+ T Cells to Promote Therapeutic Anti-Tumor Immunity Inhibiting the Growth of Mouse Sarcoma [DOI]
37. 37 VEGFR1 Activity Modulates Myeloid Cell Infiltration in Growing Lung Metastases but Is Not Required for Spontaneous Metastasis Formation [DOI]
38. 38 Regulatory dendritic cells: New targets for cancer immunotherapy [DOI]
39. 39 RETRACTED: Immunosuppressive networks in the tumour environment and their effect in dendritic cells [DOI]
40. 40 Changes of Th17/Tc17 and Th17/Treg cells in endometrial carcinoma [DOI]
41. 41 Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study [DOI]
42. 42 Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy [DOI]
43. 43 MIP-2 Recruits NKT Cells to the Spleen During Tolerance Induction [DOI]
44. 44 Immunologic mechanisms of antitumor activity [DOI]
45. 45 Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts [DOI]
46. 46 Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides [DOI]
47. 47 Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours
48. 48 Sipuleucel-T for the Treatment of Advanced Prostate Cancer [DOI]
49. 49 Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.
50. 50 Retraction notice to “Immunosuppressive networks in the tumour environment and their effect in dendritic cells” [Biochim. Biophys. Acta (1795) (2009) 16–24] [DOI]
51. 51 Hallmarks of Cancer: The Next Generation [DOI]
52. 52 Foxp3 programs the development and function of CD4+CD25+ regulatory T cells [DOI]
53. 53 Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia [DOI]
54. 54 Nuclear factor-κB in cancer development and progression [DOI]
55. 55 Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia [DOI]
56. 56 Innate or Adaptive Immunity? The Example of Natural Killer Cells [DOI]
57. 57 Transcriptional regulation of macrophage polarization: enabling diversity with identity [DOI]
58. 58 Distinct Role of Macrophages in Different Tumor Microenvironments [DOI]
59. 59 Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy [DOI]
60. 60 The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies [DOI]
61. 61 Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression [DOI]
62. 62 Immunosuppressive Strategies that are Mediated by Tumor Cells [DOI]
63. 63 An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation [DOI]
64. 64 Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host [DOI]
65. 65 The Pancreas Cancer Microenvironment [DOI]
66. 66 Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses [DOI]
67. 67 Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes [DOI]
68. 68 Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature [DOI]
69. 69 Th17 and Regulatory T Cells in Mediating and Restraining Inflammation [DOI]
70. 70 Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity [DOI]
71. 71 Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses [DOI]
72. 72 Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells [DOI]
73. 73 Cross-Talk between Myeloid-Derived Suppressor Cells and Macrophages Subverts Tumor Immunity toward a Type 2 Response [DOI]
74. 74 Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells [DOI]
75. 75 Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4 + CD25 + regulatory T cell proliferation [DOI]
76. 76 Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function [DOI]
77. 77 Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism [DOI]
78. 78 Cancer-related inflammation: Common themes and therapeutic opportunities [DOI]
79. 79 The Prognostic Value of FoxP3+ Tumor-Infiltrating Lymphocytes in Cancer: A Critical Review of the Literature [DOI]
80. 80 Human CD25+CD4+ T Suppressor Cell Clones Produce Transforming Growth Factor β, but not Interleukin 10, and Are Distinct from Type 1 T Regulatory Cells [DOI]
81. 81 Dendritic Cells in the Cancer Microenvironment [DOI]
82. 82 NK Cells and Cancer [DOI]
83. 83 Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species [DOI]
84. 84 Differentiation and gene expression profile of tumor-associated macrophages [DOI]
85. 85 Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells [DOI]
86. 86 Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth [DOI]
87. 87 Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders [DOI]
88. 88 Regulatory T Cells in the Control of Autoimmunity: the Essential Role of Transforming Growth Factor β and Interleukin 4 in the Prevention of Autoimmune Thyroiditis in Rats by Peripheral CD4+CD45RC− Cells and CD4+CD8− Thymocytes [DOI]
89. 89 Strategies of Tumor Immune Evasion [DOI]
90. 90 Resistance to Metastatic Disease in STAT6-Deficient Mice Requires Hemopoietic and Nonhemopoietic Cells and Is IFN-γ Dependent [DOI]
91. 91 Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms [DOI]
92. 92 The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients [DOI]
93. 93 Dynamic Education of Macrophages in Different Areas of Human Tumors [DOI]
94. 94 Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma [DOI]
95. 95 Cutting Edge: A Novel, Human-Specific Interacting Protein Couples FOXP3 to a Chromatin-Remodeling Complex That Contains KAP1/TRIM28 [DOI]
96. 96 Small Rho GTPases Mediate Tumor-Induced Inhibition of Endocytic Activity of Dendritic Cells [DOI]
97. 97 Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.

Cited by 0

No indexed citations yet.

Related research

• Oncolytic Parvoviruses: An Emerging Frontier for Targeted Gene Therapy of Human Carcinoma — shares topic coverage
• Targeting PD-1: A Computational Approach to Discover Small Molecule Inhibitors for Cancer Treatment — shares topic coverage
• Computational Identification of YQG-Like Small-molecule Inhibitors Targeting TIM-3 for Cancer Immunotherapy — shares topic coverage
• The Gut–NET–ICB Axis: Microbial Metabolite-Mediated Regulation of NETosis and Implications for Cancer Immunotherapy — shares topic coverage
• Emergent New Anti PD-1/PD-L1 Small Molecules for Cancer Treatment — shares topic coverage